Cephalalgia最新文献

{"title":"No evidence of intracranial hypotension in persistent post-traumatic headache: A magnetic resonance imaging study.","authors":"Henrik W Schytz, Emil Smilkov, Ian Carroll, Tomas Dobrocky, Haidar M Al-Khazali, Daniel Tolnai, Rigmor H Jensen, Faisal Mohammad Amin","doi":"10.1177/03331024251325556","DOIUrl":"10.1177/03331024251325556","url":null,"abstract":"<p><p>BackgroundPersistent post-traumatic headache (PTH) is frequent, and intracranial hypotension may be an important cause of PTH. The present study aimed to examine whether magnetic resonance imaging (MRI) signs of intracranial hypotension are more frequent in people with persistent PTH than in healthy controls (HCs).MethodsAdults with persistent PTH attributed to mild traumatic brain injury and age- and sex-matched HCs attended a single non-contrast, brain MRI 3T session. Fluid attenuated inversion recovery T1- and T2-weighted sequences were acquired to assign a modified Bern score. The score ranges from 0 to 9 points, with higher scores indicating a greater probability of cerebrospinal fluid (CSF) leakage leading to intracranial hypotension. The primary outcome was the difference in modified Bern score between participants with persistent PTH and HCs. All images were examined by a certified neuroradiologist who was blinded to the group status.ResultsImaging data from 97 participants with persistent PTH and 96 age- and sex-matched HCs were eligible for analyses. A modified Bern score of ≤2 was present in 90 (93%) participants with persistent PTH and 85 (89%) HCs, indicating a low probability of CSF leak. None of the persistent PTH participants or the HCs had a score of >4. There were no significant differences in modified Bern scores between participants with persistent PTH and HCs.ConclusionsThere is a low prevalence of typical MRI Bern score signs of intracranial hypotension in PTH or HCs. Thus, intracranial hypotension is unlikely to be an underlying factor in persistent PTH attributed to mild traumatic brain injury.Trial RegistrationThe study was registered on ClinicalTrials.gov (identifier: NCT03791515). Date of registration 2018-12-29.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"45 4","pages":"3331024251325556"},"PeriodicalIF":5.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143966682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What is the evolutionary disadvantage of migraine?","authors":"Marco Lisicki, Jean Schoenen","doi":"10.1177/03331024251327361","DOIUrl":"https://doi.org/10.1177/03331024251327361","url":null,"abstract":"","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"45 4","pages":"3331024251327361"},"PeriodicalIF":5.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143762956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"International Classification of Headache Disorders-4 - <i>Work in progress 2</i>.","authors":"Peter J Goadsby, Stefan Evers, Amy A Gelfand, Richard B Lipton, Arne May, Patricia Pozo-Rosich, Jean Schoenen, Todd J Schwedt, Cristina Tassorelli, Gisela Terwindt, Shuu-Jiun Wang","doi":"10.1177/03331024251325550","DOIUrl":"https://doi.org/10.1177/03331024251325550","url":null,"abstract":"","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"45 4","pages":"3331024251325550"},"PeriodicalIF":5.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143966677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors for airplane headache: A multivariable logistic regression analysis in a population of career flight personnel.","authors":"Johannes Prottengeier, Isabelle Kaiser, Andreas Moritz, Fabian Konrad","doi":"10.1177/03331024251329837","DOIUrl":"https://doi.org/10.1177/03331024251329837","url":null,"abstract":"<p><p>IntroductionAirplane headache (AH) is a lesser-known headache disorder that occurs during and is caused by air travel. Although considered rare and current prevalence figures vary widely, it potentially affects millions annually. Risk factors for AH have not yet been adequately investigated, and so the present study aimed to identify risk factors associated with AH among a large cohort of frequent flyers.MethodsWe conducted a survey using an extensive questionnaire that highlighted 30 potential risk factors for AH. We compared individuals experiencing AH with those without headaches and those with other types of headaches. Two multivariate logistic regression models were developed from risk variables and assessed using the area under the curve (AUC) of their receiver operating characteristics, with 10-fold cross-validation applied for reliability.ResultsIn total, 2237 questionnaires were analysed; 279 participants reported aircraft headache, while 1563 reported other forms of headache. Model selection resulted in two significant models: model 1, distinguishing AH from no headache, and model 2, differentiating AH from other headaches. Both models demonstrated promising accuracy, with AUC values of 0.794 and 0.595, respectively.ConclusionsAH notably affects productivity and workdays lost. The identified risk factors align with risk factors for headache in general, as well as headache at high altitudes. Interestingly, folic acid supplementation could have a positive, protective effect. Further research is warranted to explore these relationships and potential preventive strategies.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"45 4","pages":"3331024251329837"},"PeriodicalIF":5.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143964648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is gastroesophageal reflux disease a comorbidity of burning mouth syndrome? A cross-sectional, real-world study.","authors":"Linman Li, Shuangshuang Wu, Luling Wang, Xinming Zhang, Yajuan Cui, Zhimin Yan","doi":"10.1177/03331024251336139","DOIUrl":"https://doi.org/10.1177/03331024251336139","url":null,"abstract":"<p><p>BackgroundThe etiology of burning mouth syndrome (BMS) patients remains unclear and systemic conditions concurrently with BMS are viewed with greater scrutiny. The present study aimed to reveal whether gastroesophageal reflux disease (GERD) is the possible comorbidity of BMS.MethodsIn our study, a real-world design was employed, enrolling BMS patients from an oral medicine clinic and capturing data in a non-interventional, cross-sectional setting. Endoscopy and the Gastroesophageal Reflux Disease Questionnaire (GERDQ) were used to assess the potential GERD patients. Demographics, clinical symptoms and signs were compared between both the GERD and non-GERD groups, and GERDQ ≥8 and <8 groups. Meanwhile, GERDQ items were assessed to determine predictive value.ResultsIn total, 124 BMS patients with GERDQ scores were enrolled, of whom 84 patients were screened by endoscopy. GERD were confirmed by endoscopy in 30.95% (26/84) of patients with BMS, whereas 69.05% (58/84) showed no definite evidence of GERD. When GERDQ with a cutoff score of 8 was utilized for screening all 124 BMS patients, 25.8% (32/124) had GERDQ scores ≥8. When considering the endoscopic diagnosis as the golden standard due to the low availability of 24-h pH monitoring, the specificity and sensitivity were 79.2% and 46.2% respectively. Clinically, altered taste (<i>p </i>= 0.022) and thickened tongue coating (<i>p </i>= 0.001) were significantly more common in the GERDQ ≥8 group, whereas no significant difference was revealed between endoscopy approved GERD and non-GERD groups.ConclusionsGERD may represent a potential systemic comorbidity in BMS patients and GERDQ might serve as the screening tool assisting healthcare professionals. Altered taste and thickened tongue coating might be suggestive for potential GERD symptoms in BMS patients. Further research is desired to elucidate the mechanisms linking such conditions.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"45 4","pages":"3331024251336139"},"PeriodicalIF":5.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Migraine and the white matter microstructure controversy: Time for a methodological reset?","authors":"Roberta Messina, Catherine D Chong","doi":"10.1177/03331024251339431","DOIUrl":"https://doi.org/10.1177/03331024251339431","url":null,"abstract":"","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"45 4","pages":"3331024251339431"},"PeriodicalIF":5.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and tolerability of atogepant in the prevention of migraine: A real life, prospective, multicentric study (the STAR study).","authors":"Fabrizio Vernieri, Luigi Francesco Iannone, Flavia Lo Castro, Gabriele Sebastianelli, Federico De Santis, Michele Corrado, Marilena Marcosano, Raffaele Ornello, Licia Grazzi, Danilo Antonio Montisano, Francesco De Cesaris, Antonio Munafò, Luisa Fofi, Alberto Doretti, Gloria Vaghi, Francesca Pistoia, Delfina Ferrandi, Stefania Battistini, Simona Sacco, Simona Guerzoni, Claudia Altamura","doi":"10.1177/03331024251335927","DOIUrl":"10.1177/03331024251335927","url":null,"abstract":"<p><p>BackgroundFocusing on calcitonin gene-related peptide (CGRP) as a specific target has changed and improved migraine management. After the positive results of monoclonal antibodies directed to the CGRP pathway (anti-CGRP mAbs), randomized controlled trials also demonstrated the efficacy of gepants in migraine prevention. The present study aimed to assess the effectiveness of atogepant in preventing migraine after a 12-week treatment in clinical practice.MethodsAdult patients with a clinical indication for atogepant 60 mg daily were screened for participation in this multicentric prospective observational cohort study. At baseline (T0) and after 12 weeks (T3) since the first atogepant administration, monthly migraine days (MMDs), monthly headache days (MHDs) and monthly acute medications (MAMs) were assessed. The co-primary endpoints were the changes in MMDs from T0 to T3 and the percentage of T3 Responders (those with a reduction of MMDs ≥50%, i.e. 50% response rate (RR)). At T0 and T3, we also collected the Headache Impact Test (HIT-6), the Migraine Disability Assessment (MIDAS) questionnaire, the Migraine Treatment Optimization Questionnaire-6 (mTOQ-6), the Migraine-Specific Quality-of-Life Questionnaire (MSQ), the 12-item Allodynia Symptom Checklist (ASC-12) and the Migraine Interictal Burden Scale (MIBS-4).ResultsOne hundred and six patients (56/106 (52.8%) with chronic migraine (CM), 93/106 (87.7%) female, aged 50.6 ± 13.2 years) from 10 Italian centers completed the 12-week observation since the first atogepant tablet intake. From baseline to T3, a reduction of 6.9 MMDs (SD 9.7; <i>p</i> < 0.001) was achieved in the whole group and, specifically, of -4.9 (SD 6.6; <i>p</i> < 0.001) in episodic migraine (EM) and of -8.6 (SD 11.7; <i>p</i> < 0.001) in CM patients. Overall, 60/106 (56.6%) of patients were Responders (60.0% in the EM and 46.4% in the CM group). Non-Responders previously experienced more ineffective treatments than Responders with anti-CGRP mAbs (65.2% vs. 43.3%, respectively, <i>p</i> = 0.031) and with onabotulinumtoxinA (56.5% vs. 28.3%, <i>p</i> = 0.005), and presented more medication overuse at baseline (55.7% vs. 44.3%, p = 0.003). However, no baseline characteristics were significantly associated with the Responder status in the multiple regression analysis. For T0 to T3, MAMs, MIDAS, ASC-12 and mTOQ-6 reduced (<i>p</i> ≤ 0.001 consistently), and MSQ role-function restriction increased (<i>p</i> = 0.026), whereas HIT-6 and MIBS-4 did not change. Only seven subjects (7/106, 6.6%) dropped out of atogepant treatment: four for lack of effectiveness and three for adverse events or poor tolerability.ConclusionsThe STAR study demonstrates the effectiveness and tolerability of atogepant 60 mg at 12 weeks in a real-world setting. Previous ineffective anti-CGRP mAbs were not a relevant prognostic factor.Trial RegistrationThe study was preregistered on clinicaltrial.gov, NCT06414044.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"45 4","pages":"3331024251335927"},"PeriodicalIF":5.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to \"Methodological considerations in assessing the impact of CGRP monoclonal antibodies on blood pressure\".","authors":"Britt W H van der Arend, Floor C van Welie, Jan Versijpt, Antoinette Maassen Van Den Brink, Gisela M Terwindt","doi":"10.1177/03331024251329506","DOIUrl":"https://doi.org/10.1177/03331024251329506","url":null,"abstract":"","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"45 4","pages":"3331024251329506"},"PeriodicalIF":5.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Internet and social media's role in migraine education: Headache or not headache?","authors":"Faraidoon Haghdoost","doi":"10.1177/03331024251336152","DOIUrl":"https://doi.org/10.1177/03331024251336152","url":null,"abstract":"","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"45 4","pages":"3331024251336152"},"PeriodicalIF":5.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multidisciplinary headache treatment with work-focus in Norway: An observational study.","authors":"Oda V Lunder, Torbjørn Wisløff, Linn-Marie Wølneberg, Aina Kristin Paulsen, Linda Hagen Aasbakken, Inger Louise Hole, Ingvild Vøllo Eliassen, Kjersti Aaseth, Espen S Kristoffersen, Kjersti G Vetvik","doi":"10.1177/03331024251332572","DOIUrl":"https://doi.org/10.1177/03331024251332572","url":null,"abstract":"<p><p>BackgroundHeadache-related sick leave is increasing in Norway. In cooperation with the Norwegian Labour and Welfare Administration we established the first Norwegian multidisciplinary headache clinic for patients with current or recurrent sick leave due to headaches. The primary objective of this study was to evaluate treatment effects on headache frequency and sick leave, and secondly to identify predictors for improvement and return-to-work.MethodsA team comprising neurologists, nurses, physiotherapists, psychologists, and job specialists treated patients aged 18-67 years with headache-related sick leave. Validated questionnaires and semi-structured interviews were conducted at baseline, 3, 6, and 12 months. Mixed effects linear and logistic regression was performed with headache days and sick leave as outcomes.ResultsOne hundred and one patients completed the 12-month follow-up. The median monthly headache days decreased from 24 (Interquartile range [IQR], 15.5-30) at baseline to 10 (IQR, 4-20) at 12 months (<i>p</i> < 0.001). Headache-related sick leave declined from 53.5% to 33.7% (<i>p</i> < 0.001). Migraine diagnosis and long-term sick leave at baseline negatively predicted for return-to-work, while female sex and low baseline headache frequency predicted favorable clinical outcomes.ConclusionMultidisciplinary treatment reduced headache frequency and increased work attendance. Our findings have potential implications for healthcare policy and resource allocation.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"45 4","pages":"3331024251332572"},"PeriodicalIF":5.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}